Immune to Cancer: The CRI Blog
-
ASH18 Preview: Blood Cancer Immunotherapy Developments at 60th American Society of Hematology Meeting
The 2018 American Society of Hematology meeting will showcase a variety of basic and clinical advances in…
-
FDA Approves Pembrolizumab Immunotherapy for Advanced Liver Cancer
Patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, can now receive PD-1…
-
Voices Amongst the Crowd at 2018 TCS New York City Marathon
Sixteen Team CRI runners ran the 26.2 mile 2018 TCS New York City Marathon and raised an…
-
Fundraising and Fighting Cancer with Music for a Cause
On September 28, 2018, Conversing with Oceans organized a concert and fundraiser in the Bronx to support…
-
CRI Celebrates its 65th Birthday
On Thursday, October 25, the Cancer Research Institute held its annual awards gala to celebrate its 65th…
-
CICON18 Day 4 Update: The Role of Bacteria; Technologies to Advance Cancer Immunotherapy
The final day of CICON18 explored two diverse areas—technology and the microbiome—that both have the…
-
CICON18 Day 3 Update: Targeting Tumor Mutations with Vaccine-Based Immunotherapies
The third day of CICON18 explored cutting-edge strategies to identify and target the mutated markers that distinguish…
-
Dr. James P. Allison, CRI Scientific Director, Awarded 2018 Nobel Prize along with Dr. Tasuku Honjo
Dr. Allison’s discoveries and determination led to the development of the first FDA-approved checkpoint immunotherapy
-
Cemiplimab Becomes First Treatment Approved for Advanced Cutaneous Squamous Cell Carcinoma
Immunotherapy is now approved for patients with advanced forms of the second most common form of skin…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.